EGFR and non-small cell lung carcinoma: To further investigate the broad therapeutic potential of API against NSCLC, we examined the effects of API on cell migration and invasion of NSCLC cells harboring different EGFR statuses including the exon 19 deletion (del E746-A750) and L858R/T790 M.